Table 2.
Baseline characteristics
| Age (years; mean ± SD) | 29.87 ± 4.96 |
|---|---|
| Disease (number of patients/percentages) | |
| Crohn’s Disease | 22 (58%) |
| Ileal (L1) | 4 (18%) |
| Colonic (L2) | 5 (23%) |
| Ileocolonic (L3) | 13 (59%) |
| Ulcerative colitis | 16 (42%) |
| Proctitis (E1) | 3 (19%) |
| Left-sided (E2) | 7 (44%) |
| Pancolitis (E3) | 6 (37%) |
| Previous surgery for Crohn’s Disease | |
| Treatment at baseline | 7 (32%) |
| No medication | 5 (13%) |
| Corticosteroids | 2 (5%) |
| Aminosalicylates | 12 (32%) |
| Thiopurines | 11 (29%) |
| Anti-TNF-α | 15 (39%) |
| Vedolizumab | 4 (11%) |
| Ustekinumab | 3 (7.9%) |
| Clinical remission at start of pregnancy (HBI < 4 or SCCAI < 3) |
32 (84%) |
| Weeks pregnant at baseline (median and range) | 11 (5–33) |
Abbreviations: SD, standard deviation; IBD, inflammatory bowel disease; TNF-α, tumor necrosis factor; HBI, Harvey-Bradshaw Index; SCCAI, Simple Clinical Colitis Activity Index.